Skip to content

Author

Zhanpeng Zhang

We have 1 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Case report Open access Jul 2026

Onatasertib re-sensitizes refractory nasopharyngeal carcinoma to immunotherapy: a Case Report

A case study highlighting the significant efficacy of onatasertib, a dual mechanistic target of rapamycin (mTOR) 1/2 inhibitor, in overcoming resistance to immunotherapy in patients with R/M-NPC.

Peipei Zhang, Zhanpeng Zhang, Jun Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.